MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: PIK3R1 Therapeutische Implikation

Raw xml | Download


<Observation xmlns="http://hl7.org/fhir">
  <id value="mii-exa-mtb-kim-musterperson-TherapeutischeImplikation-PIK3R1"/>
  <meta>
    <profile
             value="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapeutische-implikation|2027.0.0-ballot.1"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: Observation mii-exa-mtb-kim-musterperson-TherapeutischeImplikation-PIK3R1</b></p><a name="mii-exa-mtb-kim-musterperson-TherapeutischeImplikation-PIK3R1"> </a><a name="hcmii-exa-mtb-kim-musterperson-TherapeutischeImplikation-PIK3R1"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-mii-pr-mtb-therapeutische-implikation.html">MII PR MTB Therapeutische Implikation</a> version: 2027.0.0-ballot.1</p></div><p><b>MII EX MTB Empfehlung Evidenzgraduierung</b>: <span title="Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad m3}">Preclinical data (in vitro, in vivo models or functional genomics studies) demonstrate that the biomarker predicts response to a specific drug treatment, supported by scientific rationale.</span></p><p><b>status</b>: Final</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span>, <span title="Codes:{http://terminology.hl7.org/CodeSystem/v2-0074 GE}">Genetics</span></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs therapeutic-implication}">Therapeutic Implication</span></p><p><b>subject</b>: <a href="Patient-PatientKimMusterperson.html">Kim Musterperson  (no stated gender), DoB: 1956-03-14</a></p><p><b>derivedFrom</b>: <a href="Observation-mii-exa-mtb-kim-musterperson-EinfacheVariante-PIK3R1.html">Observation Genetic variant assessment</a></p><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs conclusion-string}">Conclusion Text</span></p><p><b>value</b>: Ausweislich praeklinischer Daten liegt ein Ansprechen auf MEK-Inhibition nahe (PMID: 31209687, EL m3).</p></blockquote><blockquote><p><b>component</b></p><p><b>code</b>: <span title="Codes:{http://loinc.org 51963-7}">Medication assessed [ID]</span></p><p><b>value</b>: <span title="Codes:{http://fhir.de/CodeSystem/bfarm/atc L01EE}">Mitogen-aktivierte Proteinkinase (MEK)-Inhibitoren</span></p></blockquote></div>
  </text>
  <extension
             url="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-ex-mtb-empfehlung-evidenzgraduierung">
    <valueCodeableConcept>
      <coding>
        <system
                value="https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad"/>
        <code value="m3"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <status value="final"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/observation-category"/>
      <code value="laboratory"/>
      <display value="Laboratory"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/v2-0074"/>
      <code value="GE"/>
    </coding>
  </category>
  <code>
    <coding>
      <system
              value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
      <code value="therapeutic-implication"/>
      <display value="Therapeutic Implication"/>
    </coding>
  </code>
  <subject>🔗 
    <reference value="Patient/PatientKimMusterperson"/>
  </subject>
  <derivedFrom>🔗 
    <reference
               value="Observation/mii-exa-mtb-kim-musterperson-EinfacheVariante-PIK3R1"/>
  </derivedFrom>
  <component>
    <code>
      <coding>
        <system
                value="http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/tbd-codes-cs"/>
        <code value="conclusion-string"/>
      </coding>
    </code>
    <valueString
                 value="Ausweislich praeklinischer Daten liegt ein Ansprechen auf MEK-Inhibition nahe (PMID: 31209687, EL m3)."/>
  </component>
  <component>
    <code>
      <coding>
        <system value="http://loinc.org"/>
        <code value="51963-7"/>
        <display value="Medication assessed [ID]"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://fhir.de/CodeSystem/bfarm/atc"/>
        <code value="L01EE"/>
        <display value="Mitogen-aktivierte Proteinkinase (MEK)-Inhibitoren"/>
      </coding>
    </valueCodeableConcept>
  </component>
</Observation>